TYK2 Inhibitor Scores Two Wins Outside Plaque Psoriasis

[ad_1]

(MedPage Today) — ORLANDO — The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here.
More than half of patients with psoriatic arthritis (PsA) had at least…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/aad/114579

Author :

Publish date : 2025-03-10 20:15:00

Copyright for syndicated content belongs to the linked Source.